Clinical TrialsA twice daily administration of ATRN-119 is predicted to help maintain therapeutic levels of the drug in patients potentially enhance the drug’s efficacy.
Management And ResourcesThe company has a strong management team, good assets/programs, and cash runway into 2Q26.
Safety ProfileThe safety profile for ATRN-119 continues to be favorable, which is a departure from other ATRi drugs in development that faced toxicity issues.